Combined subconjunctival Atropine and intracameral epinephrine for pupil dilation in phacoemulsification .A comparative study .
Not Applicable
Recruiting
- Conditions
- Eye DiseasesSurgerycataract
- Registration Number
- PACTR201608001739424
- Lead Sponsor
- Dar El Oyoun hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Cases of bilateral visually significant cataract
Exclusion Criteria
Poor pupil dilation , traumatic cataract , uveitic cataract , glaucoma patients ,optic nerve diseases and the use of systemic or topical mydriatics or miotics
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie atropine's synergistic effect with epinephrine on pupil dilation during phacoemulsification?
How does combined subconjunctival atropine and intracameral epinephrine compare to standard pupil dilation techniques in cataract surgery?
Are there specific ocular biomarkers that predict enhanced pupil dilation response to atropine-epinephrine combination therapy?
What are the potential adverse events associated with subconjunctival atropine and intracameral epinephrine in phacoemulsification procedures?
What alternative combination therapies involving anticholinergics and adrenergic agonists are being explored for intraoperative pupil maintenance in cataract surgery?